Site Map - XHANCE® (fluticasone propionate)
Full Prescribing Information Instructions for Use Patient Information Patient Site
Goes to the Full Prescribing Information page Full Prescribing Information Goes to Instructions for Use page Instructions for Use Goes to the Patient Information page Patient Information Goes to the Patient Site Patient Site
Goes to the Home page XHANCE® (fluticasone propionate) nasal spray 93 mcg logo
  • Home
  • Clinical Trial Results
    • Efficacy
    • Safety
  • Exhalation Delivery System
  • Dosing & Administration
  • Affordability & Access
  • Resources

Site Map

  • Pdf about full prescribing informationFull Prescribing Information
  • Pdf about important information about XHANCEInstructions for Use
  • Pdf about patient informationPatient Information
  • Pdf about patient sitePatient Site
  • Clinical Trial Results
    • Goes to the Efficacy pageEfficacy
    • Goes to the Safety pageSafety
  • Goes to the Exhalation Delivery System pageExhalation Delivery System
  • Goes to the Dosing and Administration pageDosing & Administration
  • Affordability & AccessAffordability & Access
  • ResourcesResources
  • Goes to the Contact Us pageContact Us
  • Goes to the Privacy Policy pagePrivacy Policy
  • Goes to the Terms of Use pageTerms of Use
  • Goes to the Site Map pageSite Map
+
INDICATIONS
XHANCE is a corticosteroid indicated for the treatment of chronic rhinosinusitis with or without nasal polyps in adults.
IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS:
Hypersensitivity to any ingredient in XHANCE.

WARNINGS AND PRECAUTIONS:

  • Local nasal adverse reactions, including epistaxis, erosion, ulceration, septal perforation, Candida albicans infection, and impaired wound healing, can occur. Monitor patients periodically for signs of possible changes on the nasal mucosa.  Avoid use in patients with recent nasal ulcerations, nasal surgery, or nasal trauma until healing has occurred.
  • Glaucoma and cataracts may occur with long-term use. Consider referral to an ophthalmologist in patients who develop ocular symptoms or use XHANCE long-term.
  • Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, contact dermatitis, rash, hypotension, and bronchospasm) have been reported after administration of fluticasone propionate.  Discontinue XHANCE if such reactions occur.
  • Immunosuppression and infections can occur, including potential increased susceptibility to or worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infection; ocular herpes simplex).  Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients.
  • Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage in susceptible individuals.  If such changes occur, discontinue XHANCE slowly.
  • Assess for decrease in bone mineral density initially and periodically thereafter.

ADVERSE REACTIONS:

  • Chronic rhinosinusitis without nasal polyps:  The most common adverse reactions (incidence ≥ 3%) are epistaxis, headache, and nasopharyngitis.
  • Chronic rhinosinusitis with nasal polyps:  The most common adverse reactions (incidence ≥ 3%) are epistaxis, nasal septal ulceration, nasopharyngitis, nasal mucosal erythema, nasal mucosal ulcerations, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis.

DRUG INTERACTIONS:
Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. May increase risk of systemic corticosteroid effects.

USE IN SPECIFIC POPULATIONS:
Hepatic impairment.  Monitor patients for signs of increased drug exposure.

Please see Full Prescribing Information pdf opensfull Prescribing Information, including Instructions for Use.

  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Site Map

This site is intended for healthcare professionals in the United States.
OPTINOSE®, XHANCE®, EXHALATION DELIVERY SYSTEM™ and EDS® are trademarks of OptiNose, Inc.

Click to go optinose web site Optinose® logo
©2024 OptiNose US, Inc. All rights reserved.  XHA-24-10078 12/2024

Are you a US healthcare professional?

Click to reject No

You are about to leave the XHANCE HCP website.

Are you sure?

Click to accept Yes
Your browser doesn't support HTML5 video tag.